Analyzing key commercial dynamics, import reliance, and growth parameters in the expanding Sub-Saharan pharmaceutical landscape.
Over 90% of all finished pharmaceutical formulations and critical medical equipment in Zambia are imported from international manufacturers.
Zambia's national import bill for pharmaceutical and medical supplies reaches approximately $310 Million (K5 Billion) annually.
The Zambian pharmaceutical and device market is projected to expand at an annual growth rate of 8.5% between 2026 and 2032.
A snapshot of the demand, import reliance and projected growth shaping opportunities for manufacturers entering Zambia.
Zambia's heavy reliance on imported therapeutics presents an enormous market opportunity for international manufacturers. With local manufacturing representing only 10% of national consumption, the country actively relies on strategic consulting and ZPPA-registered import channels to procure, clear, and distribute essential medicines.
Our regulatory and tender advisory acts as the local gateway, helping global pharmaceutical developers safely navigate ZAMRA product registrations and coordinate large-scale public bidding pipelines.
Zambia's main pharmaceutical imports originate from India, South Africa, and Europe (including Denmark and Belgium). Our consultancy leverages deep local market expertise to structure framework bidding for these global manufacturers.
The strategy designates essential medical and pharmaceutical supplies as high-priority codes, utilizing preferential public procurement and framework agreements to award contracts to ZPPA-registered entities.
To streamline national spending and optimize clinical availability, the Zambian government has unveiled the **Pharmaceutical Manufacturing Strategy (2024-2028)**. This initiative aims to establish long-term framework contracts and encourage structured import compliance.
By registering under ZPPA Supplier ID `124884` and complying with approved procurement codes `51000000` (Drugs) and `42000000` (Equipment), A ONE AFRO LIMITED is perfectly positioned to help international principals secure these long-term government framework contracts.
The projected 8.5% market expansion is driven by a convergence of rising healthcare demands, a growing population, and expanding clinical networks. Additionally, the government's focus on digital healthcare platforms, mobile diagnostics, and decentralized clinical networks is improving drug access across all provinces.
Our pharmaceutical data analytics provide the precise market metrics, price assessments, and consumption tracking required to successfully project demand and manage inventory cycles across these growing networks.
Decentralizing medicine distribution from central warehouses to remote rural health nodes is a national priority, driving massive opportunities in cold chain logistics, GDP-compliant warehousing, and tracking databases.
A ONE AFRO LIMITED provides the regulatory, data, and tender expertise required to successfully place and distribute your pharmaceutical and medical portfolios in Zambia.
Connect with our Advisory Team